国产亚洲欧美日韩俺去了,人妻无码久久精品,亚洲人成影院在线观看,亚洲AV永久无码精品表情包

再鼎醫藥是一家致力于研究、開(kāi)發(fā)和銷(xiāo)售創(chuàng )新藥物的制藥企業(yè)。再鼎醫藥針對目前尚無(wú)良好治療手段的疾病領(lǐng)域開(kāi)發(fā)新藥，以改善全球病人的生活質(zhì)量。再鼎醫藥通過(guò)內部研發(fā)和授權許可等方式建立全面的產(chǎn)品線(xiàn)。我們希望公司開(kāi)發(fā)的新藥能夠遏制疾病，并為患者帶來(lái)顯著(zhù)療效。

再鼎醫藥創(chuàng )建于2013年，公司擁有一支在全球制藥企業(yè)和研發(fā)機構富有經(jīng)驗的世界級管理團隊。這支擁有卓越成功經(jīng)驗的創(chuàng )始人團隊被譽(yù)為中國快速發(fā)展的生物技術(shù)產(chǎn)業(yè)的先驅?zhuān)鴰ьI(lǐng)多個(gè)成品成功獲得中國和美國食品藥品監督管理局的認可。這支團隊最先在中國嘗試新藥快速審批途徑并獲得批準，同時(shí)也與多個(gè)跨國制藥巨頭建立了長(cháng)期的戰略合作伙伴關(guān)系。在再鼎醫藥，團隊將繼續投身于在中國為世界開(kāi)發(fā)高質(zhì)量的創(chuàng )新藥。

再鼎醫藥獲得數家生物醫藥領(lǐng)域的全球頂級投資機構的支持，包括啟明創(chuàng )投基金，凱鵬華盈中國基金，紅杉資本和泰福資本。這些投資機構都將堅定地支持再鼎醫藥成長(cháng)為生物醫藥領(lǐng)域的國際領(lǐng)先企業(yè)。

Zai Lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. Our vision is to address the largest unmet medical needs and transform patients’ lives around the world. We take a unique approach to combine both in-licensed products and internal R&D to achieve a rich pipeline. We believe our drug candidates can be truly disease modifying and bring significant benefits to patients.

The company was founded in 2013 by a group of industry veterans. The founders are known as pioneers in China’s fast advancing biotech industry with a proven track record for successful Chinese CFDA and US FDA filings and approvals. Our senior management team introduced fast regulatory approval pathways in China and developed a variety of partnership models with multinational pharmaceutical companies. We endeavor to conduct world class clinical development in China and beyond.

Zai Lab has strong backing from a leading group of healthcare investors including Qiming Venture Partners, Kleiner Perkins Caufield & Byers, Sequoia Capital and TF Capital. Our investors are committed to support Zai Lab to become a global biopharmaceutical leader based in China.